Treatment of Mild-to-Moderate COVID-19 in Ambulatory Patients at High Risk for Progression
Clinical Scenario
This protocol addresses ambulatory (non-hospitalized) patients with mild-to-moderate COVID-19 who maintain SpO₂ above 94% on room air and do not require supplemental oxygen, but who carry risk factors placing them at high risk for progression to severe disease.
Mild-to-moderate illness is defined as SpO₂ greater than 94% not requiring supplemental oxygen. Identifying high-risk ambulatory patients early is critical for timely intervention.
Treatment Approach
The approach centres on antiviral therapy initiated early in the illness course — within days of symptom onset. Specific agent selection and dosing are tailored to the individual patient.
The complete regimen, selection criteria, and full dosing algorithm are available in the structured protocol below.
Treatment Goal
The primary objective is avoidance of COVID-19‑related hospitalization and COVID-19‑related medically attended visits through day 28.
References
DOI: 10.1093/cid/ciac724
- In ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests nirmatrelvir/ritonavir initiated within 5 days of symptom onset rather than no nirmatrelvir/ritonavir.
- Mild-to-moderate illness is defined as patient with SpO2 >94% not requiring supplemental oxygen.
- Among patients (ambulatory or hospitalized) with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests remdesivir initiated within 7 days of symptom onset rather than no remdesivir.
- Among ambulatory patients with mild-to-moderate COVID-19 at high risk for progression to severe disease, the IDSA guideline panel suggests treatment with anti–SARS-CoV-2 monoclonal antibodies with activity against the predominant regional variants within 7 days of symptom onset rather than no anti–SARS-CoV-2 monoclonal antibodies.
View source ↗